Cargando…
It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo
Autor principal: | Nannini, Luis J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969308/ https://www.ncbi.nlm.nih.gov/pubmed/36861059 http://dx.doi.org/10.1183/23120541.00555-2022 |
Ejemplares similares
-
It is time to end our love affair with short-acting β(2)-agonists in asthma
por: Crooks, Michael G., et al.
Publicado: (2022) -
Short-Acting β(2)-Agonist Use Could Be a Confounding Factor for Interpreting Increased IL-6
por: Nannini, Luis J.
Publicado: (2020) -
Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Baraldi, Eugenio, et al.
Publicado: (2022) -
Reply to Baraldi and Piacentini: Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Duijts, Liesbeth, et al.
Publicado: (2022) -
Our Love Affair with Drugs: The History, The Science, The Politics
por: Hallworth, Amelia
Publicado: (2020)